S413
Clinical - Gynaecological
ESTRO 2026
protocols after EBRT to detect recurrence across all risk groups in endometrial cancer. References: 1. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. doi:10.1016/j.annonc.2022.05.0092. British Gynaecological Cancer Society recommendations and guidance on patient- initiated follow-up (PIFU). doi:10.1136/ijgc- 2019-001176 Keywords: Endometrial cancer, recurrence, follow-up A prospective audit of treatment interruptions in cervical cancer radiotherapy and impact of a mobile- based patient tracking system in Bangladesh Dr. Mahbuba Akhter Tania Radiation Oncology, National Institute Of Cancer Research & Hospital, Mohakhali, Dhaka, Dhaka, Bangladesh Digital Poster 939 Purpose/Objective: Interruptions during curative radiotherapy (RT) for cervical cancer prolong overall treatment time (OTT) and compromise tumour control—an enduring challenge in low- and middle-income countries (LMICs).This study prospectively quantified the frequency, duration, and determinants of RT interruptions at a national cancer centre and evaluated the effect of a mobile phone call + SMS–based patient-tracking system on improving treatment adherence and quality indicators. Material/Methods: From September–November 2025, a prospective observational audit enrolled 30 consecutive women with histologically confirmed cervical carcinoma treated with external-beam RT (45–50.4 Gy in 25–28 fractions) ± weekly cisplatin (40 mg/m ² ) at the National Institute of Cancer Research &
Hospital (NICRH), Dhaka.Data were prospectively captured using an ESTRO- aligned dataset including demographics, ECOG, FIGO stage, chemotherapy, weekly weight, and interruptions ≥ 3 days.Interruptions were classified as machine/technical, toxicity-related, or social/logistic.At mid-study a dual-mode tracking system was introduced: automated SMS reminders before each fraction and follow-up phone calls by technologists for missed sessions.Endpoints: (1) proportion with ≥ 3-day interruption; (2) change in OTT; (3) treatment-completion rate. Results: Median age = 52 years (range 38–68); 80 % FIGO IIB–IIIB; 70 % received concurrent cisplatin.Pre-intervention, 12 patients (40 %) experienced interruptions ≥ 3 days (median 5 days, IQR 3–8); causes: machine downtime (33 %), toxicity (27 %), social/logistic (40 %).Median OTT = 56 days (IQR 51– 63).Following introduction of the mobile call + SMS system, interruption rate fell to 20 % and median OTT improved to 50 days (p = 0.03).Treatment compliance rose from 84 % → 94 %, and satisfaction surveys showed > 90 % patients felt “better supported.”No grade ≥ 3 toxicities were observed; grade 1–2 nausea (53 %), diarrhoea (40 %), and fatigue (37 %) predominated.Data completeness = 98 %. Conclusion: Nearly half of cervical-cancer patients initially experienced avoidable RT interruptions, predominantly non-clinical.Embedding a low- cost digital tracking model—daily SMS reminders and human follow-up calls— significantly shortened OTT and improved compliance without additional staffing or infrastructure.This scalable, context- appropriate innovation demonstrates how LMIC departments can operationalise ESTRO’s quality-and-equity framework, offering a replicable model for global radiotherapy access improvement. References: 1. Datta NR et al. Clin Oncol (R Coll Radiol).
Made with FlippingBook - Share PDF online